Sangamo Biosciences, Inc.  

(Public, NASDAQ:SGMO)   Watch this stock  
Find more results for SGMO
5.66
-0.31 (-5.19%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.60 - 5.96
52 week 5.30 - 19.25
Open 5.96
Vol / Avg. 1.14M/1.08M
Mkt cap 396.47M
P/E     -
Div/yield     -
EPS -0.45
Shares 70.05M
Beta 2.19
Inst. own 77%
Feb 11, 2016
Sangamo BioSciences Inc at Leerink Partners Global Healthcare Conference - 2:40PM EST - Add to calendar
Feb 9, 2016
Q4 2015 Sangamo BioSciences Inc Earnings Call - 5:00PM EST - Add to calendar
Feb 9, 2016
Q4 2015 Sangamo BioSciences Inc Earnings Release - 4:00PM EST - Add to calendar
Jan 12, 2016
Sangamo BioSciences Inc at JPMorgan Healthcare Conference
Dec 3, 2015
Sangamo BioSciences Inc at Boston Biotech Genetic Rx Conference
Dec 2, 2015
Sangamo BioSciences Inc at Piper Jaffray Healthcare Conference
Nov 18, 2015
Sangamo BioSciences Inc at Jefferies Autumn Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -107.89% -57.59%
Operating margin -148.03% -58.38%
EBITD margin - -57.19%
Return on average assets -16.04% -13.76%
Return on average equity -18.38% -16.09%
Employees 102 -
CDP Score - -

Address

501 Canal Blvd
RICHMOND, CA 94804-3559
United States - Map
+1-510-9706000 (Phone)
+1-510-2368951 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Company's lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Company's clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimer’s disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Officers and directors

William R. Ringo Jr. Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Edward O. Lanphier II President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
H. Ward Wolff Chief Financial Officer, Principal Financial and Accounting Officer, Executive Vice President
Age: 66
Bio & Compensation  - Reuters
Geoffrey M. Nichol Executive Vice President - Research and Development
Age: 59
Bio & Compensation  - Reuters
Dale G. Ando M.D. Vice President - Therapeutic Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
H. Stewart Parker Director
Age: 59
Bio & Compensation  - Reuters
Paul B. Cleveland Independent Director
Age: 59
Bio & Compensation  - Reuters
Stephen G. Dilly Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
John W. Larson Independent Director
Age: 75
Bio & Compensation  - Reuters
Steven J. Mento Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters